MENLO PARK, Cal., April 07, 2022 (Globe Newswire) — Corecept Therapeutics Incorporated (NASDAQ:CORT), a commercial-scale company, is engaged in drug discovery and drug discovery to treat serious endocrine, metabolic, oncologic and neurological disorders by modulating and engaged in development. Impact of the hormone cortisol today announced the appointment of three individuals to commercial and development leadership roles.
Daniel Einhorn, MD, FACP, joins FACE, Corcept as Vice President, Endocrine Strategy; Amiel Balagtas has joined as Vice President, Development Operations; and Lindah Drelling, MD, as Vice President of Global Oncology Development. Dr. Einhorn will report to Sean Madk, President of Corcept Endocrinology. Mr. Balagatas and Dr. Drelling will report to Bill Guyer, PharmD, Corcept’s Chief Development Officer.
The CEO of Corecept, Joseph K. “Dan, Amiel and Lindah bring deep and diverse expertise to Corcept, and I am confident that their leadership in significant commercial and development efforts will allow us to make significant strides for patients,” Belanoff said. , “I look forward to their impact on our ability to advance pipeline programs and ensure that our medicines reach the people who may benefit from them.”
Daniel Einhorn, MD, FACP, FACE — Vice President, Endocrine Strategy
Dr. Einhorn has over 30 years of experience as a clinical endocrinologist, lecturer, researcher and developer of clinical practice guidelines. Prior to joining Corcept, he served as President of Diabetes and Endocrine Associates, Medical Director of the Scripps Whittier Diabetes Institute, Past-Clinical Professor of Medicine at the University of California San Diego, and Associate Editor of the Journal of Diabetes. Dr. Einhorn is past president of the American Association of Clinical Endocrinologists and past president of the American College of Endocrinology. He earned a BA from Yale, an MD from Tufts University, and completed his postgraduate training at Harvard Medical School’s Beth Israel Hospital. Dr. Einhorn has been the recipient of many awards and honors, including the Endocrine Society’s Outstanding Clinical Endocrinologist Award. In 2022 he was made a Master of the American College of Endocrinology and a Fellow of the Royal Society of Medicine.
Amiel Balagatas — Vice President, Development Operations
Mr. Balagatas brings to his role over 30 years of scientific and operational experience. He joined Corcept after 23 years at Gilead Sciences in seniority-raising roles in Clinical Operations, Marketing and Medical Affairs. He most recently served as executive director of development systems at Gilead. In this capacity, Mr. Balagatas leads a global team responsible for process and systems improvement across the development organization, including portfolio strategy and management, clinical research, regulatory affairs and clinical data science. Prior to Gilead, Mr. Balagatas worked as a clinical trial coordinator at Stanford and the University of California, San Francisco, managing both the pharmaceutical company and NIH-supported clinical studies. He is a graduate of the University of California, Los Angeles and holds a Master of Business Administration degree from Golden Gate University.
Lindah Drelling, MD — Vice President, Global Oncology Development
Dr. Drelling is a Hematologist/Oncologist with over 25 years of experience in pharmaceutical and biotechnology drug development and academic medicine. She joined the company from Spectrum Pharmaceuticals, where she held the role of Senior Vice President, Clinical Development. She has held diverse leadership positions of increasing seniority at Amgen, Aventis, Five Prime Therapeutics and Gilead, and managed the Clinical Operations, Clinical Pharmacology, Safety, Biometrics and Medical teams. Throughout her career, Lindah has led the design, execution and interpretation of data from Phase 1 to 3 trials, global regulatory submissions and post-marketing studies. Dr. Drelling has an undergraduate, MBA, and MD degree from the University of Colorado, where he also completed his internal medicine residency and a hematology/oncology fellowship.
About Corcept Therapeutics
Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property, including their composition and their use to treat a variety of serious disorders. is included. The company is conducting clinical trials of its flagship cortisol modulator as a potential treatment for Cushing’s syndrome, ovarian, adrenal and prostate cancer, weight gain due to use of antipsychotic drugs and liver disease. Corcept drug Korlym It was the first drug approved by the US Food and Drug Administration to treat patients with Cushing’s syndrome.
The statements made in this press release, in addition to statements of historical fact, are forward-looking statements based on our current plans and expectations which are subject to risks and uncertainties that could cause our actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, our ability to conduct our business, conduct our clinical trials, and achieve our other goals during the COVID-19 pandemic; Risks related to the development of product candidates, including their clinical characteristics, rate of advancement and timing of regulatory submissions, mandates, oversight and other requirements; and the scope and protective power of our intellectual property. These and other risks are set out in our SEC filings, which are available on our website and the SEC’s website. In this press release, forward-looking statements include the performance of our commercial and clinical programs and the ability of Mr. Balagatas and Drs Einhorn and Drelling to contribute to them. We disclaim any intention or duty to update the forward-looking statements made in this press release.